Mr. Mark Thompson reports

CONCORDIA HEALTHCARE CORP. ANNOUNCES NAME CHANGE TO CONCORDIA INTERNATIONAL CORP. AND COMMENTS ON BREXIT'S IMPACT ON THE COMPANY'S BUSINESS

Concordia Healthcare Corp. has changed its name to Concordia International Corp.

The name change was previously approved by the board of directors of the company and the company's shareholders. It is expected that the common shares of the company will begin trading under the new name on June 30, 2016. The company's stock symbol will remain CXR on the Toronto Stock Exchange and CXRX on Nasdaq.

"The name Concordia International Corp. better reflects the global nature of our business," said Mark Thompson, chairman and chief executive officer of Concordia. "With sales channels in more than 100 counties and a diverse therapeutic mix of products, we are excited about the opportunity ahead of us."

Concordia's consolidated business consists of three operating segments:

1. Concordia North America, which has a diversified product portfolio that focuses primarily on the United States pharmaceutical market;
2. Orphan drugs, which are intended to provide growth opportunities through the expansion into new indications and new markets for existing or acquired orphan drugs;
3. Concordia International, which comprises the AMCo group of companies acquired by Concordia on Oct. 21, 2015.

Concordia International consists of a diversified portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies throughout the world.

The British-pound-denominated free cash flow from Concordia International's 2016 operations is naturally hedged in 2016 by its British-pound-denominated liabilities. In 2016, these payment obligations include five million British pounds of principal and 30 million British pounds of interest payments in respect of the 500-million-British-pound term loan, an earn-out of 144 million British pounds payable to the former owners of AMCo, and approximately 38 million British pounds related to purchase consideration liabilities associated with AMCo's prior acquisitions, subject to certain product performance metrics being achieved.

The depreciation of the British pound relative to the U.S. dollar does not impact the company's ability to service its debt and meet its earn-out obligations in 2016. Beyond 2016, the company will monitor its hedging needs.

"Operationally, our Concordia International segment is continuing to perform as expected," continued Mr. Thompson.

We seek Safe Harbor.